RxDoctor Payments Data

Claire Noell, MD

Dermatology · Boston, MANPI 1457779589

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,754 of the $4,907 with a category attached, or 76.5%. 29 manufacturers reported payments, led by Pfizer at 24.2% of the total. Reporting peaked in 2023 at $1,965 and has fallen 53.3% since, to $918 in 2025.

$4,907in general payments, 2019–2025

Across 142 payments — averaging $34.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$696
  • Johnson & Johnson$433
  • Galderma Laboratories, L.p.$358
  • Regeneron Healthcare Solutions, Inc.$267
  • E.r. Squibb & Sons, L.L.C.$260
  • plus $2K from 23 others
$24,995in research payments, 2019–2025

Across 6 payments — averaging $4165.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avita Medical Americas, LLC$25K

What the payments were for

  • Consulting fees$1754%
  • Travel & lodging$68914%
  • Food & beverage$3,75476%
  • Education$2906%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,907 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$108,929
Medicare patients
357
Services billed
3,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate27$1,374
Tacrolimus11$1,062
Tretinoin17$776
Metronidazole15$563
Clindamycin Phosphate14$538
Doxycycline Hyclate16$400
Ketoconazole21$292
Triamcinolone Acetonide25$218
Finasteride13$215

Paid to pharmacies, not to this prescriber.

Other dermatology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →